/
SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform fungerps , a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have genera…
The business is unprofitable at the operating level (-78.03% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 449.9% YoY with margins expanding 912.8pp.
Negative free cash flow of -$5M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$20M
▲ +449.9% YoY
Net Income (TTM)
-$25M
▲ +59.6% YoY
Op. Margin
-119.95%
▲ +912.8pp YoY
ROIC
-42.72%
▲ +20.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$6M
▲ +78.0% YoY
Op. Cash Flow (TTM)
-$6M
▲ +78.0% YoY
Net Debt
-$57M
Net Cash Position
Cash & Equiv.
$59M
Continue Research